Effect of decarboxylase inhibition and neuroleptic drugs on the DOPA level in rat brain.
D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001593:Benzyl Compounds / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D002421:Caudate Nucleus / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D002746:Chlorpromazine / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000378:metabolism*; D004357:Drug Synergism; D004789:Enzyme Activation; D005260:Female; D006220:Haloperidol / Q000494:pharmacology; D006834:Hydrazines / Q000494:pharmacology; D008297:Male; D010636:Phenols / Q000494:pharmacology; D051381:Rats; D014149:Tranquilizing Agents / Q000494:pharmacology*; D014446:Tyrosine 3-Monooxygenase
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001593:Benzyl Compounds; D006834:Hydrazines; D010636:Phenols; D014149:Tranquilizing Agents; D004295:Dihydroxyphenylalanine; D014446:Tyrosine 3-Monooxygenase; D006220:Haloperidol; D002746:Chlorpromazine